Patent · US Active

2,4-Pyrimidinediamine compounds and their uses

US7642351B2 · kind B2 · utility

98Cited by

51References

14Claims

0Family size

Assignee

Rogel Pharmaceuticals, Inc. · US

Inventors

Rajinder Singh · Belmont, US
Ankush Argade · Foster City, US
Donald Payan · Hillsborough, US
Susan Molineaux · San Francisco, US
Sacha Holland · San Francisco, US
Jeffrey Clough · Redwood City, US
Holger Keim · Irvine, US
Somasekhar Bhamidipati · Foster City, US
Catherine Sylvain · Burlingame, US
Hui Li · Santa Clara, US
Alexander B. Rossi · Reedsport, US

Key dates

Filing date	Oct 5, 2006
Grant date	Jan 5, 2010
Priority date	—
Expiry date	Oct 5, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07F5/027
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.